elderly patients with chronic myeloid leukemia Effects and outcome of a policy of intermittent imatinib treatment in

doi:10.1182/blood-2013-01-480194Prepublished online May 15, 2013;2013 121: 5138-5144€€€€Bigazzi, Bruno Mario Cesana, Gianantonio Rosti and Michele BaccaraniBruno Martino, Tamara Intermesoli, Carmen Fava, Elisabetta Abruzzese, Mario Tiribelli, Catia Turri, Michela Bergamaschi, Patrizia Pregno, Ester Pungolino, Fabio Stagno, Massimo Breccia,Iacobucci, Antonio De Vivo, Nicoletta Testoni, Fausto Castagnetti, Gabriele Gugliotta, Diamante Domenico Russo, Giovanni Martinelli, Michele Malagola, Cristina Skert, Simona Soverini, Ilaria€

[1]  I. Flinn,et al.  Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up , 2012, Leukemia.

[2]  M. Baccarani,et al.  Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.

[3]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[4]  D. Marin,et al.  The Natural History of RTQ-PCR Levels After the Achievement of Complete Molecular Remission (CMR): Implications for ‘Stopping' Studies , 2011 .

[5]  Simona Soverini,et al.  BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. , 2011, Blood.

[6]  M. Höglund,et al.  Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Gherlinzoni,et al.  Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. , 2011, Blood.

[8]  Philippe Rousselot,et al.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. , 2010, The Lancet. Oncology.

[9]  J. Melo,et al.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR , 2010, Leukemia.

[10]  M. Gordon.  Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia , 2010 .

[11]  C. Carcassi,et al.  Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. , 2009, Blood.

[12]  M. Baccarani,et al.  Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. , 2009, Blood.

[13]  M. Baccarani,et al.  Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party. , 2009 .

[14]  N. Cross,et al.  Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.

[15]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[16]  Martin C. Müller,et al.  Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. , 2008, Blood.

[17]  J. Apperley.  Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.

[18]  J. Goldman.  How I treat chronic myeloid leukemia in the imatinib era. , 2007, Blood.

[19]  M. Deininger,et al.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. , 2007, Blood.

[20]  M. Baccarani,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[21]  H. Kantarjian,et al.  Current and emerging treatment options in chronic myeloid leukemia , 2007, Cancer.

[22]  M. Baccarani,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[23]  P. Erben,et al.  Resistance to targeted therapy in chronic myelogenous leukemia. , 2007, Seminars in hematology.

[24]  Francisco Cervantes,et al.  Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.

[25]  Simona Soverini,et al.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.

[26]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[27]  R. A’Hern.  Sample size tables for exact single‐stage phase II designs , 2001, Statistics in medicine.

[28]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.